AI assistant
IMMUCELL CORP /DE/ — Director's Dealing 2026
Jan 29, 2026
34519_dirs_2026-01-29_be98f66e-e6de-4b63-96c3-ff5248770c29.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: IMMUCELL CORP /DE/ (ICCC)
CIK: 0000811641
Period of Report: 2026-01-27
Reporting Person: te Boekhorst Paul Francis Olivier (Director, President and CEO)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2026-01-27 | Stock Options (right to buy) | $6.265 | A | 110000 | Acquired | 2036-01-27 | Common Stock (110000) | Direct |
Footnotes
F1: Option grant made to Mr. te Boekhorst in connection with his employment as President and CEO. The option shall be treated as an incentive stock option to the maximum extent permitted by the Internal Revenue Code of 1986, as amended, with the balance treated as nonqualified stock option. One hundred percent of the stock option will vest when the Issuer's net operating income for four consecutive calendar quarters equals or exceeds 300% of the Issuer's audited net operating income for its 2025 fiscal year.